$4550
[Research Report] The gastroparesis market was valued at US$ 4,338.61 million in 2019 and is projected to reach US$ 6,025.11 millionby 2027; it is expected to grow at a CAGR of 4.3% from 2020 to 2027.
Gastroparesis is a medical condition characterized by the disability of stomach to empty itself of food in the usual way. Damaged nerves such as vagus nerves and muscles associated with gastric motility may also lead to gastroparesis. The condition is commonly observed in diabetic people. Gastroparesis can be classified as diabetic, idiopathic, and post-surgical on the basis of the cause. Apart from these, viral infections, nerve-related diseases, excessive narcotics and several antidepressant consumption, and amyloidosis may also lead to the onset of gastroparesis.The COVID-19 pandemic has disrupted supply chain of over-the-counter (OTC) and prescription drugs, and this is likely to limit the market growth in the next few quarters. Moreover, the emphasis of health care providers and medical industries on COVID-19 has led to the lowered focus on the diagnosis and treatment for gastroparesis, which is limiting the market growth to a certain extent.
Lucrative Regions for Gastroparesis Market
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Market Insights
Increasing Geriatric Population Accelerating Demand for Gastroparesis Treatment Modalities
Gastric emptying is associated with the coordination among the motor activity of proximal stomach, distal stomach, and duodenum. These internal organs are controlled by the feedback mechanism from neural signals generated through the interaction between nutrients and small intestine. Aging leads to diminished homeostatic regulations of physiologic functions, along with the slowing of gastric emptying. Moreover, it influences motor and sensory functions. In addition, geriatric population is highly vulnerable to gastroparesis due to factors such as the poor oral medication absorption, inadequate appetite regulation, and postprandial glycemia. According to the 2019 revision of World Population Prospects, 1 in 6 people would be aged more than 65 by 2050, with an increase from 1 in 11 in 2019. Furthermore, according to the same study, one in four people in Europe and North America is projected to be aged over 65 by 2050. Also, the number of people with age more than 80 would reach 426 million by 2050 from 143 million in 2019. Thus, the continuous increase in aging population, coupled with the rise in issues associated with gastric emptying among these populations, drives the gastroparesis market growth.
Type-Based Insights
On the basis of type, the gastroparesis market is segmented into idiopathic, diabetic, post-surgical, and others. The idiopathic segment held the largest share of the market in 2019, while the diabetic segment is estimated to register the highest CAGR during the forecast period.
Gastroparesis Market, by Type – 2019 and 2027
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Drug Class Type-Based Insights
The gastroparesis market, based on drug class type, is segmented into prokinetic agents, antiemetic agents, and botulinum toxin injections. The prokinetic agents segment held the largest market share in 2019 and is estimated to register the highest CAGR during 2020–2027.
Distribution Channel-Based Insights
On the basis of distribution channel, the gastroparesis market is segmented into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment held the largest share of the market in 2019, and the market for the same is estimated to grow at the highest CAGR from 2020 to 2027.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Gastroparesis Market: Strategic Insights
Market Size Value in US$ 4,338.61 Million in 2019 Market Size Value by US$ 6,025.11 million by 2027 Growth rate CAGR of 4.3% from 2020-2027 Forecast Period 2020-2027 Base Year 2020
Akshay
Have a question?
Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Gastroparesis Market: Strategic Insights
| Market Size Value in | US$ 4,338.61 Million in 2019 |
| Market Size Value by | US$ 6,025.11 million by 2027 |
| Growth rate | CAGR of 4.3% from 2020-2027 |
| Forecast Period | 2020-2027 |
| Base Year | 2020 |
Akshay
Have a question?
Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
The gastroparesis market players have been adopting the strategy of product innovations to cater to dynamic customer demands, which also allows them to maintain their brand name in the global market.
Gastroparesis Market – by Type
- Idiopathic
- Diabetic
- Post-surgical
- Others
Gastroparesis Market – by Drug Class Type
- Prokinetic Agents
- Botulinum Toxin Injections
- Antiemetic Agents
Gastroparesis Market – by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
GastroparesisMarket– by Geography
- North America
- US
- Canada
- Mexico
- Europe
- France
- Germany
- Italy
- UK
- Spain
- Rest of Europe
- Asia Pacific(APAC)
- China
- India
- South Korea
- Japan
- Australia
- Rest of APAC
- Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Rest of MEA
- South Americaand Central America (SCAM)
- Brazil
- Argentina
- Rest of SCAM
Company Profiles
- EVOKE PHARMA
- Bausch Health Companies Inc. (Salix Pharmaceuticals, Ltd.)
- Johnson and Johnson Services, Inc.
- Allergan Plc
- NEUROGASTRX, INC.
- TEVA PHARMACEUTICAL INDUSTRIES LTD
- Pfizer Inc.
- ANI Pharmaceuticals, Inc.
- Ipca Laboratories Ltd.
- Cinrx Pharma, LLC (Cindome Pharma)
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Gastroparesis Type , Drug Class Type , and Distribution Channel
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Saudi Arabia, South Africa, South Korea, Spain, United Arab Emirates, United Kingdom, United States
Frequently Asked Questions
Gastroparesis is a condition where the stomach cannot empty itself of food in the usual way. Moreover, the damaged nerves such as vagus nerves and muscles associated with gastric motility may also lead to gastroparesis. The condition is substantially observed in the diabetic population. Gastroparesis can be classified as diabetic, idiopathic, and post-surgical on the basis of causes. Apart from these viral infections, nerve-related diseases, excessive consumption of narcotics and some antidepressants, and amyloidosis may also lead to the occurrence of gastroparesis.
The growth of the market is attributed to some key driving factors such as increasing prevalence of diabetes and growing geriatric population.
The gastroparesis market majorly consists of the players such as EVOKE PHARMA, Bausch Health Companies Inc.(Salix Pharmaceuticals, Ltd.), Johnson And Johnson Services, Inc., Allergan Plc, NEUROGASTRX, INC., TEVA PHARMACEUTICAL INDUSTRIES LTD, Pfizer Inc., ANI Pharmaceuticals, Inc., Ipca Laboratories Ltd., And Cinrx Pharma, LLC (Cindome Pharma) amongst others.
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Global Gastroparesis Market – By Type
1.3.2 Global Gastroparesis Market – By Drug Class Type
1.3.3 Global Gastroparesis Market – By Distribution Channel
1.3.4 Global Gastroparesis Market – By Geography
2. Gastroparesis Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Global Gastroparesis Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America– PEST Analysis
4.2.2 Europe– PEST Analysis
4.2.3 Asia Pacific– PEST Analysis
4.2.4 Middle East & Africa- PEST Analysis
4.2.5 South and Central America- PEST Analysis
4.3 Expert Opinion
5. Gastroparesis Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Diabetes Mellitus Prevalence
5.1.2 Increasing Geriatric Population
5.2 Market Restraints
5.2.1 Side Effects of Gastroparesis Drugs
5.3 Market Opportunities
5.3.1 Surging Investments and Financial Assistance for Research
5.4 Future Trends
5.4.1 Emphasis on Gastric Electrical Stimulation Therapy Research
5.5 Impact Analysis
6. Gastroparesis Market – Global Analysis
6.1 Global Gastroparesis Market Revenue Forecast And Analysis
6.2 Global Gastroparesis Market, By Geography - Forecast And Analysis
6.3 Market Positioning of Key Players
7. Gastroparesis Market Analysis – By Type
7.1 Overview
7.2 Gastroparesis Market Revenue Share, by Type (2019 and 2027)
7.3 Idiopathic
7.3.1 Overview
7.3.2 Idiopathic: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
7.4 Diabetic
7.4.1 Overview
7.4.2 Diabetic: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
7.5 Post-Surgical
7.5.1 Overview
7.5.2 Post-Surgical: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
7.6 Others
7.6.1 Overview
7.6.2 Others: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
8. Gastroparesis Market Analysis – By Drug Class Type
8.1 Overview
8.2 Gastroparesis Market Revenue Share, by Drug Class Type (2019 and 2027)
8.3 Prokinetic Agents
8.3.1 Overview
8.3.2 Prokinetic Agents: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
8.4 Botulinum Toxin Injection
8.4.1 Overview
8.4.2 Botulinum Toxin Injection: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
8.5 Antiemetic Agents
8.5.1 Overview
8.5.2 Antiemetic Agents: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
9. Gastroparesis Market Analysis – By Distribution Channel
9.1 Overview
9.2 Gastroparesis Market Share, by Distribution Channel, 2019 and 2027, (%)
9.3 Retail Pharmacies
9.3.1 Overview
9.3.2 Retail Pharmacies: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
9.4 Hospital Pharmacies
9.4.1 Overview
9.4.2 Hospital Pharmacies: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
9.5 Others
9.5.1 Overview
9.5.2 Others: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
10. Gastroparesis Market – Geographic Analysis
10.1 North America: Gastroparesis Market
10.1.1 Overview
10.1.2 North America: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.1.3 North America Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
10.1.4 North America Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
10.1.5 North America Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
10.1.6 North America: Gastroparesis Market, by Country, 2019 & 2027 (%)
10.1.7 US: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.1.7.1 US: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.1.7.2 US Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
10.1.7.3 US Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
10.1.7.4 US Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
10.1.8 Canada: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.1.8.1 Canada: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.1.8.2 Canada Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
10.1.8.3 Canada Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
10.1.8.4 Canada Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
10.1.9 Mexico: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.1.9.1 Mexico: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.1.9.2 Mexico Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
10.1.9.3 Mexico Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
10.1.9.4 Mexico Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
10.2 Europe: Gastroparesis Market
10.2.1 Overview
10.2.2 Europe: Gastroparesis Market - Revenue and Forecast to 2027 (USD Million)
10.2.3 Europe Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
10.2.4 Europe Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
10.2.5 Europe Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
10.2.6 Europe: Gastroparesis Market, by Country, 2019 & 2027 (%)
10.2.7 Germany: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.2.7.1 Germany: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.2.7.2 Germany Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
10.2.7.3 Germany Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
10.2.7.4 Germany Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
10.2.8 UK: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.2.8.1 UK: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.2.8.2 UK Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
10.2.8.3 UK Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
10.2.8.4 UK Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
10.2.9 France: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.2.9.1 France: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.2.9.2 France Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
10.2.9.3 France Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
10.2.9.4 France Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
10.2.10 Spain: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.2.10.1 Spain: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.2.10.2 Spain Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
10.2.10.3 Spain Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
10.2.10.4 Spain Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
10.2.11 Italy: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.2.11.1 Italy: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.2.11.2 Italy Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
10.2.11.3 Italy Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
10.2.11.4 Italy Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
10.2.12 Rest of Europe: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.2.12.1 Rest of Europe: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.2.12.2 Rest of Europe Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
10.2.12.3 Rest of Europe Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
10.2.12.4 Rest of Europe Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
10.3 Asia Pacific: Gastroparesis Market
10.3.1 Overview
10.3.2 Asia Pacific: Gastroparesis Market - Revenue and Forecast to 2027 (USD Million)
10.3.3 Asia Pacific Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
10.3.4 Asia Pacific Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
10.3.4.1 Asia Pacific Gastroparesis Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
10.3.5 Asia Pacific: Gastroparesis Market, by Country, 2019 & 2027 (%)
10.3.6 China: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.3.6.1 China: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.3.6.2 China Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
10.3.6.3 China Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
10.3.6.3.1 China Gastroparesis Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
10.3.7 Japan: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.3.7.1 Japan: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.3.7.2 Japan Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
10.3.7.3 Japan Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
10.3.7.3.1 Japan Gastroparesis Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
10.3.8 India: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.3.8.1 India: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.3.8.2 India Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
10.3.8.3 India Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
10.3.8.4 India Gastroparesis Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
10.3.9 South Korea: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.3.9.1 South Korea: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.3.9.2 South Korea Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
10.3.9.3 South Korea Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
10.3.9.4 South Korea Gastroparesis Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
10.3.10 Australia: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.3.10.1 Australia: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.3.10.2 Australia Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
10.3.10.3 Australia Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
10.3.10.4 Australia Gastroparesis Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
10.3.11 Rest of Asia Pacific: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.3.11.1 Rest of Asia Pacific: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.3.11.2 Rest of Asia Pacific Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
10.3.11.3 Rest of Asia Pacific Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
10.3.11.4 Rest of Asia Pacific Gastroparesis Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
10.4 Middle East & Africa: Gastroparesis Market
10.4.1 Overview
10.4.2 Middle East & Africa: Gastroparesis Market - Revenue and Forecast to 2027 (US$ Million)
10.4.3 Middle East & Africa Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
10.4.4 Middle East & Africa Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
10.4.5 Middle East & Africa Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
10.4.6 Middle East & Africa: Gastroparesis Market, by Country, 2019 & 2027 (%)
10.4.7 Saudi Arabia: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.4.7.1 Saudi Arabia: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.4.7.2 Saudi Arabia Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
10.4.7.3 Saudi Arabia Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
10.4.7.4 Saudi Arabia Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
10.4.8 UAE: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.4.8.1 UAE: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.4.8.2 UAE Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
10.4.8.3 UAE Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
10.4.8.4 UAE Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
10.4.9 South Africa: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.4.9.1 South Africa: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.4.9.2 South Africa Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
10.4.9.3 South Africa Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
10.4.9.4 South Africa Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
10.4.9.5 Rest of Middle East and Africa: Gastroparesis Market - Revenue and Forecasts to 2027 (USD Million)
10.4.9.5.1 Rest of Middle East and Africa: Gastroparesis Market- Revenue and Forecasts to 2027 (USD Million)
10.4.9.6 Rest of Middle East and Africa Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
10.4.9.7 Rest of Middle East and Africa Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
10.4.9.8 Rest of Middle East and Africa Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
10.5 South and Central America: Gastroparesis Market
10.5.1 Overview
10.5.2 South and Central America: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.5.3 South and Central America Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
10.5.4 South and Central America Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
10.5.5 South and Central America Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
10.5.6 South and Central America: Gastroparesis Market, by Country, 2019 & 2027 (%)
10.5.7 Brazil: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.5.7.1 Brazil: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.5.7.2 Brazil Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
10.5.7.3 Brazil Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
10.5.7.4 Brazil Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
10.5.8 Argentina: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.5.8.1 Argentina: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.5.8.2 Argentina Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
10.5.8.3 Argentina Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
10.5.8.4 Argentina Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
10.5.8.5 Rest of South and Central America: Gastroparesis Market- Revenue and Forecasts to 2027 (USD Million)
10.5.8.5.1 Rest of South and Central America: Gastroparesis Market- Revenue and Forecasts to 2027 (USD Million)
10.5.8.6 Rest of South and Central America Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
10.5.8.7 Rest of South and Central America Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
10.5.8.8 Rest of South and Central America Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
11. Impact of COVID-19 Pandemic on Global Gastroparesis Market
11.1 North America: Impact Assessment of COVID-19 Pandemic
11.2 Europe: Impact Assessment Of COVID-19 Pandemic
11.3 Asia Pacific: Impact Assessment of COVID-19 Pandemic
11.4 Middle East and Africa: Impact Assessment of COVID-19 Pandemic
11.5 South and Central America: Impact Assessment of COVID-19 Pandemic
12. Gastroparesis Market –Industry Landscape
12.1 Overview
12.2 Growth Strategies in the Gastroparesis Market, 2018-2020
12.3 Inorganic Growth Strategies
12.3.1 Overview
12.4 Organic Growth Strategies
12.4.1 Overview
13. Company Profiles
13.1 Evoke Pharma
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Allergan Plc.
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 NEUROGASTRX, INC.
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Bausch Health Companies Inc.( Salix Pharmaceuticals)
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Johnson and Johnson Services, Inc.
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 TEVA PHARMACEUTICAL INDUSTRIES LTD
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Pfizer Inc.
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 ANI Pharmaceuticals, Inc.
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 Ipca Laboratories Ltd
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 CinRx Pharma, LLC (CinDome Pharma)
13.10.1 Business Description
13.10.2 Products and Services
13.10.3 Financial Overview
13.10.4 SWOT Analysis
13.10.5 Key Developments
14. Appendix
14.1 About The Insight Partners
14.2 Glossary of Terms
LIST OF TABLES
Table 1. North America Gastroparesis Market, by Type– Revenue and Forecast to 2027 (USD Million)
Table 2. North America Gastroparesis Market, by Drug Class Type– Revenue and Forecast to 2027 (USD Million)
Table 3. North America Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
Table 4. US Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 5. US Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
Table 6. US Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
Table 7. Canada Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 8. Canada Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
Table 9. Canada Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
Table 10. Mexico Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 11. Mexico Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
Table 12. Mexico Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
Table 13. Europe Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 14. Europe Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
Table 15. Europe Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
Table 16. Germany Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 17. Germany Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
Table 18. Germany Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
Table 19. UK Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 20. UK Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
Table 21. UK Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
Table 22. France Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 23. France Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
Table 24. France Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
Table 25. Spain Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 26. Spain Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
Table 27. Spain Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
Table 28. Italy Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 29. Italy Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
Table 30. Italy Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
Table 31. Rest of Europe Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 32. Rest of Europe Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
Table 33. Rest of Europe Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
Table 34. Asia Pacific Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 35. Asia Pacific Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
Table 36. Asia Pacific Gastroparesis Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 37. China Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 38. China Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
Table 39. China Gastroparesis Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 40. Japan Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 41. Japan Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
Table 42. Japan Gastroparesis Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 43. India Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 44. India Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
Table 45. India Gastroparesis Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 46. South Korea Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 47. South Korea Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
Table 48. South Korea Gastroparesis Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 49. Australia Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 50. Australia Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
Table 51. Australia Gastroparesis Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 52. Rest of Asia Pacific Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 53. Rest of Asia Pacific Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
Table 54. Rest of Asia Pacific Gastroparesis Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 55. Middle East & Africa Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 56. Middle East & Africa Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
Table 57. Middle East & Africa Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
Table 58. Saudi Arabia Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 59. Saudi Arabia Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
Table 60. Saudi Arabia Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
Table 61. UAE Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 62. UAE Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
Table 63. UAE Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
Table 64. South Africa Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 65. South Africa Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
Table 66. South Africa Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
Table 67. Rest of Middle East and Africa Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 68. Rest of Middle East and Africa Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
Table 69. Rest of Middle East and Africa Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
Table 70. South and Central America Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 71. South and Central America Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
Table 72. South and Central America Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
Table 73. Brazil Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 74. Brazil Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
Table 75. Brazil Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
Table 76. Argentina Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 77. Argentina Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
Table 78. Argentina Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
Table 79. Rest of South and Central America Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 80. Rest of South and Central America Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
Table 81. Rest of South and Central America Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
Table 82. Recent Inorganic Growth Strategies in the Gastroparesis market
Table 83. Recent Organic Growth Strategies In the Gastroparesis market
Table 84. Glossary of Terms, Gastroparesis Market
LIST OF FIGURES
Figure 1. Gastroparesis Market Segmentation
Figure 2. Gastroparesis Market Segmentation, By Region
Figure 3. Gastroparesis Market Overview
Figure 4. Idiopathic Segment Held Largest Share of Gastroparesis Market
Figure 5. APAC to Show Remarkable Growth During Forecast Period
Figure 6. Gastroparesis Market, by Geography (US$ Million)
Figure 7. Global Gastroparesis Market – Leading Country Markets (US$ Million)
Figure 8. Global Gastroparesis Market, Industry Landscape
Figure 9. North America PEST Analysis
Figure 10. Europe PEST Analysis
Figure 11. Asia Pacific PEST Analysis
Figure 12. Middle East & Africa PEST Analysis
Figure 13. South and Central America PEST Analysis
Figure 14. Gastroparesis Market Impact Analysis of Drivers and Restraints
Figure 15. Global Gastroparesis Market – Revenue Forecast And Analysis – 2019- 2027
Figure 16. Global Gastroparesis Market – By Geography Forecast and Analysis – 2019- 2027
Figure 17. Market Positioning Of Key Players In Global Gastroparesis Market
Figure 18. Gastroparesis Market Revenue Share, by Type (2019 and 2027)
Figure 19. Idiopathic: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
Figure 20. Diabetic: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
Figure 21. Post-Surgical: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
Figure 22. Others: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
Figure 23. Gastroparesis Market Revenue Share, by Drug Class Type (2019 and 2027)
Figure 24. Prokinetic Agents: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
Figure 25. Botulinum Toxin Injection: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
Figure 26. Antiemetic Agents: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
Figure 27. Gastroparesis Market Share, by Distribution Channel, 2019 and 2027 (%)
Figure 28. Retail Pharmacies: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
Figure 29. Hospital Pharmacies: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
Figure 30. Others: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
Figure 31. North America: Gastroparesis Market, by Key Country – Revenue (2019) (USD Million)
Figure 32. North America Gastroparesis Market Revenue and Forecast to 2027 (USD Million)
Figure 33. North America: Gastroparesis Market, by Country, 2019 & 2027 (%)
Figure 34. US: Pharmaceutical Drug Delivery market – Revenue and Forecast to 2027 (USD Million)
Figure 35. Canada: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
Figure 36. Mexico: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
Figure 37. Europe: Gastroparesis Market, by Key Country – Revenue (2019) (USD Million)
Figure 38. Europe Gastroparesis Market Revenue and Forecast to 2027 (USD Million)
Figure 39. Europe: Gastroparesis Market, by Country, 2019 & 2027 (%)
Figure 40. Germany: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
Figure 41. UK: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
Figure 42. France: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
Figure 43. Spain: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
Figure 44. Italy: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
Figure 45. Rest of Europe: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
Figure 46. Asia Pacific: Gastroparesis Market, by Key Country – Revenue (2019) (USD Million)
Figure 47. Asia Pacific Gastroparesis Market Revenue and Forecast to 2027 (USD Million)
Figure 48. China: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
Figure 49. Japan: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
Figure 50. India: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
Figure 51. South Korea: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
Figure 52. Australia: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
Figure 53. Rest of Asia Pacific: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
Figure 54. Middle East & Africa: Gastroparesis Market, by Key Country – Revenue (2019) (USD Million)
Figure 55. Middle East & Africa Gastroparesis Market Revenue and Forecast to 2027 (USD Million)
Figure 56. Middle East & Africa: Gastroparesis Market, by Country, 2019 & 2027 (%)
Figure 57. Saudi Arabia: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
Figure 58. UAE: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
Figure 59. South Africa: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
Figure 60. Rest of Middle East and Africa: Gastroparesis Market- Revenue And Forecasts To 2027 (USD Million)
Figure 61. South and Central America: Gastroparesis Market, by Key Country – Revenue (2019) (USD Million)
Figure 62. South and Central America Gastroparesis Market Revenue and Forecast to 2027 (USD Million)
Figure 63. South and Central America: Gastroparesis Market, by Country, 2019 & 2027 (%)
Figure 64. Brazil: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
Figure 65. Argentina: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
Figure 66. Rest of South and Central America: Gastroparesis Market- Revenue And Forecasts To 2027 (USD Million)
Figure 67. Impact of COVID-19 Pandemic in North American Country Markets
Figure 68. Impact of COVID-19 Pandemic in European Country Markets
Figure 69. Impact of COVID-19 Pandemic on Gastroparesis Market in Asia Pacific Countries
Figure 70. Impact Of COVID-19 Pandemic in Middle East and Africa Market
Figure 71. Impact Of COVID-19 Pandemic in South and Central America Market
Figure 72. Growth Strategies in the Gastroparesis Market, 2018-2020
The List of Companies - Gastroparesis Market
- EVOKE PHARMA
- Bausch Health Companies Inc. (Salix Pharmaceuticals, Ltd.)
- Johnson and Johnson Services, Inc.
- Allergan Plc
- NEUROGASTRX, INC.
- TEVA PHARMACEUTICAL INDUSTRIES LTD
- Pfizer Inc.
- ANI Pharmaceuticals, Inc.
- Ipca Laboratories Ltd.
- Cinrx Pharma, LLC (Cindome Pharma)
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Related Reports
Jan 2021
Radioactive Tracer Market
Size and Forecast to 2030 - Global Analysis by Tracer Type [Technetium-99m & Tc-97m, Iodine-131, Iron-59, Lutetium-171, Rubidium (Rb-82) Chloride & Ammonia (N-13), Scandium-46, Seaborgium-269, Hassium-269, Gallium Citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), Phosphorus-32 & Chromium-51, Thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and Others], Test Type (PET, SPECT, and Others), Application (Oncology, Pulmonary, Neurology, Cardiology, and Others) End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes, And Others), and Geography
Jan 2021
Glioma Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease (Astrocytoma, Oligoastrocytoma, and Oligodendroglioma), Treatment Type (Surgery, Chemotherapy, Radiation Therapy, and Others), Grade (Low Grade and High Grade), End User (Hospital & Clinics and Ambulatory Surgical Center), and Geography
Jan 2021
Drug Delivery Market
Forecast to 2028 - Global Analysis By Route of Administration (Injectable Drug Delivery, Oral Drug Delivery, Transmucosal Drug Delivery, Topical Drug Delivery, Implantable Drug Delivery, and Ocular Drug Delivery), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and End User (Hospitals and Clinics, Home Care Settings, and Other End User)
Jan 2021
Enteral and Parenteral Medical Nutrition Market
Forecast to 2028 - Global Analysis by Indication [Elderly, Gastrointestinal Disorders (IBD, IBS, and Others), Diabetes, Cancer, Respiratory Disorders, Alzheimer's Disease, Dementia, Renal Disease, Liver Failure, Post COVID-19, and Other Indications], Nutrition Type (Supplemental and Sole–Source), Form (Liquid, Powder, and Semi–Solid), Product Type (General and Disease–Specific), Route of Administration (Oral, Tube Feed, and Parenteral), Age Group (Above 60 Years, 18–60 Years, 3–18 Years, and Below 3 Years), and Distribution Channel (Hospital Pharmacies, Retail Stores, E-Commerce, and Others)
Jan 2021
CIN & HR-HPV Treatment Market
Forecast to 2028 - Global Analysis By Disease Type (Cervical Intraepithelial Neoplasia 1, Cervical Intraepithelial Neoplasia 2, and Cervical Intraepithelial Neoplasia 3), Strain Type (HPV 16, HPV 18, and Others), Offering (Diagnostic Method and Treatment), Product Type (Kits & Reagents, Instruments, and Services), and End User (Hospitals & Clinics, Diagnostic Laboratories, Specialized Clinical Laboratories, and Others)
Jan 2021
Pharmaceutical Fluid Handling Market
Forecast to 2028 - COVID-19 Impact and Global Analysis By Offering (Equipment & Solutions and Services), Tubing (Thermoplastic Elastomers, Polyvinyl Chloride, and Silicone), Application (Fluid Handling & Management, Fluid Preparation, Integration & Automation, Buffer Management, and Others), Usage (Cough Syrup, Intravenous Product, Complex Active Pharmaceutical Ingredients, and Others), and End User (Biotechnology Companies, Pharmaceutical & Medical Companies, and Others)
Jan 2021
Enteral Medical Nutrition Market
Forecast to 2028 - COVID-19 Impact and Global Analysis By Indication (Respiratory Disorders, Cancer, Post COVID-19, Gastrointestinal Disorders, Liver Failure, and Others), Nutrition Type (Supplemental and Sole-Source), Form (Powder, Liquid, and Semi-Solid), Product (Standard Protein Diet, High Protein Diet, Fruit Juice Based Oral Nutritional Supplement, and Others), Distribution Channel (Hospital Pharmacies, Retail Stores, and Others), and Age Group [Child (Till 18 Years) and Adults (18+years)]
Jan 2021
Glycomic Therapeutics Market
Forecast to 2028 - COVID-19 Impact and Global Analysis By Class (Isolated and Synthetic), Structures [Glycoproteins, Targeting Sialic Acid, Proteoglycans, Targeting Glycosaminoglycans, Glycosylphosphatidylinositol (GPI)-Anchored Proteins & Heparin Based Glycans, Targeting Glycosphingolipids, and Others], Indications (Thrombosis & Chemoprophylaxis, Anaemia, Anti-Adhesive & Anti-Inflammatory, Cataracts, Gaucher’s Disease, MPS-1 & IV, Cancer, Alzheimer’s Disease, Influenza Type A & B, and Others), and Mode of Action [Inhibits Neuraminidase; Inhibits Heparanase and Selectins and Blocks Interactions Between Growth Factors and Heparan Sulfate; Erythropoietin & Enzyme Replacement Therapy (ERT); Tissue Plasminogen Activator; Inhibits Glucosylceramide Synthase; Interleukin 1, 2 & 3; Beta & Gamma Interferons; and Others]